We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Clanotech Receives Orphan Drug Designation in the EU

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Clanotech Receives Orphan Drug Designation in the EU"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Clanotech AB has announced that its anti-fibrotic and anti-angiogenic candidate drug CLT-28643 received orphan drug designation by the European Medicines Agency (EMA) for prevention of scarring post glaucoma filtration surgery. Karolinska Development has an 80 percent ownership in Clanotech.

Clanotech’s lead substance, an α5β1-integrin antagonist, has anti-angiogenic, anti-fibrotic and anti-inflammatory properties that are expected to benefit the wound healing processes following glaucoma surgery. The orphan drug designation will significantly shorten a future market approval process and reinforce market exclusivity for a launched product.

“We’re delighted by the positive response from the EMA, which underpins the great need for products that can improve the outcome of glaucoma surgery“, said Patrizia Caldirola, CEO, Clanotech.

“Therapies with potential for use in specialized care and orphan diseases are at the core of Karolinska Development’s investment strategy. The medical need for a safe and specific anti-fibrotic therapy in glaucoma surgery is substantial and the orphan drug designation will add significant value to this exciting pharmaceutical project”, said Bruno Lucidi, CEO, Karolinska Development.